OncoPharm
327 episodes - English - Latest episode: 5 days ago - ★★★★★ - 161 ratingsOncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
NSCLC In A Nutshell
April 19, 2024 19:16 - 11 minutes - 9.3 MBArguably, the most anticipated release of 4/19/24
HOPA '24, Site Agnositc T-DXd, & ALINA
April 11, 2024 18:46 - 14 minutes - 11.2 MBWhat I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma. Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors. Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this week's NEJM.
Tumor Lysis Syndrome
April 04, 2024 16:17 - 15 minutes - 12.9 MBTumor Lysis Syndrome (TLS) is a foundational topic for all oncology clinicians. We discuss the what, the why, prevention, and treatment.
Updates In RCC, Pancreatic Cancer, And Skin Cancer In SOT
March 28, 2024 20:55 - 13 minutes - 10.9 MBDiscussing four papers that caught our eyes from the last few weeks: Pazopanib vs. placebo following metastatectomy. Always concerning when placebo has an OS advantage. ECOG-ACRIN E2810: https://doi.org/10.1200/JCO.23.01544 Gemcitabine vs. Gem + Paclitaxel (Taxol) in pancreatic cancer patients after FOLFIRINOX: https://doi.org/10.1200/JCO.23.00795 An RNA assay to predict gemcitabine sensitivity: https://doi.org/10.1200/JCO.22.02668 Management of skin cancers with ICIs in kidney transplan...
Colon Cancer Screening Wars
March 14, 2024 20:14 - 11 minutes - 9.23 MBTwo recent publications suggest more people may be choosing non-colonoscopy screening practices in the future. One is a new stool DNA test, while the other is a blood test. How do they compare to the gold standard of colonoscopy? Cell-free DNA blood test: DOI: 10.1056/NEJMoa2304714 Next generation stool DNA test: DOI: 10.1056/NEJMoa2310336
Bladder Cancer Updates
March 07, 2024 20:20 - 12 minutes - 10.1 MBEV-302 is finally published, and you have to squint to find any major critiques. Enfortumab bedouin + pembrolizumab fully arrives as a standard 1st-line regimen of advanced urothelial cancer. Also, nivolumab gets a 1st-line FDA approval for urothelial carcinoma in conjunction with cisplatin + gemcitabine based on CHECKMATE-901.
SPARED & D-TORCH
February 29, 2024 21:22 - 12 minutes - 9.88 MBTwo nice studies have been recently published in the supportive care realm. SPARED asks if we can omit dexamethasone on days 2-4 following cisplatin-based chemotherapy. D-TORCH asks if topical diclofenac can prevent capecitabine-induced hand-foot syndrome. SPARED: https://doi.org/10.1038/s41416-023-02493-7 D-TORCH: https://doi.org/10.1200/JCO.23.01730
Lifileucel & FLAURA2 Updates
February 22, 2024 21:51 - 17 minutes - 13.8 MBAn exciting new cellular therapy, lifileucel, is approved for metastatic melanoma. The FLAURA2 trial of osimertinib + chemotherapy has led to an FDA approval, but questions remain about a possible new standard of care. And a few minor updates on tepotinib.
NAPOLI 3, POUT, & Ivosidenib - Azole DDIs
February 15, 2024 17:41 - 15 minutes - 12.1 MBNew updates on metastatic pancreatic cancer (NAPOLI-3), upper tract urothelial cancer (POUT), and the drug-drug interaction between ivosidenib and azole antifungals. NAPOLI 3: https://doi.org/10.1016/S0140-6736(23)01366-1 POUT (final OS): https://doi.org/10.1200/JCO.23.01659 Ivosidenib Azole Antifungal DDIs: https://doi.org/10.1002/cncr.35251
Small Cell Carcinoma, Prostate Edition
February 08, 2024 21:19 - 7 minutes - 6.3 MBYou know about small cell lung cancer, but let's talk about small cell carcinoma of the prostate.
Rethinking Some Fundamental Considerations
February 01, 2024 20:39 - 15 minutes - 12.5 MBIn oncology we are always asking questions about which treatment option is best. And that focus on the next best treatment may prevent us from rethinking some fundamentals of current practice. Three recent studies illustrate this and made me ask: Do we need a Port or PICC for every testicular cancer patient? Study: https://doi.org/10.1200/OP.23.00580 Editorial: https://doi.org/10.1200/OP.23.00730 Is vaginal estrogen safe if breast cancer patients? Study: https://jamanetwork.com/journals/ja...
Jan 2024 Updates...
January 25, 2024 20:31 - 15 minutes - 12.3 MB...on FDA approvals for belzutifan for RCC, pembrolizumab + cisplatin/RT for cervical cancer, erdafitinib (FGFR3 alterations only) for bladder cancer. Plus, early morning ICIs (https://doi.org/10.1016/j.ejca.2024.113571) & FLAG-Ida-GO in AML from NCRI AML 19 (https://doi.org/10.1200/JCO.23.00943)
Development Of Generic Lenalidomide with Dr. Ryan Beechinor
January 10, 2024 19:38 - 34 minutes - 26.4 MBSpecial guest Ryan Beechinor joins the pod to discuss his recent paper on the obstacles in the development of generic lenalidomide. It's a fantastic read, and this episode will be a fantastic listen! Link: https://doi.org/10.1016/j.jcpo.2023.100446
Lenalidomide
January 04, 2024 17:12 - 15 minutes - 12 MBFoundations of OncoPharm episode on lenalidomide (Revlimid) and its MOA, use, dosing, & toxicity.
2023 New Drug Review
December 21, 2023 18:00 - 14 minutes - 11.2 MBA Holiday Tradition returns as we review 14 new OncoPharm drugs approved this past year and ask Keep, Re-Gift, or Return.
ASH23 Appetizers
December 14, 2023 18:00 - 19 minutes - 15.3 MBSmall bites of updates coming out of ASH's 2023 annual meeting on CLL, multiple myeloma, and lymphoma.
VISTA
December 07, 2023 16:06 - 14 minutes - 11.4 MBOur Landmarks of OncoPharm series returns to talk about 2008's VISTA study, which ushered bortezomib into the front line setting, albeit with a now outdated alkylating agent-based backbone. VISTA (VMP vs. MP): https://www.nejm.org/doi/full/10.1056/nejmoa0801479
Gamma Secretase Inhibition et al
November 30, 2023 19:45 - 18 minutes - 14.8 MBThe recent approval of nirogacestat, the first gamma secretase inhibitor on the market, provides a great opportunity to discuss desmoid tumors and Notch signaling. Review article: https://doi.org/10.1002/onco.13627 Also, a new T-cell malignancy warning for most CAR-T products. And, is belantamab mafodotin coming back based on the DREAMM-7 results?
Repotrectinib & Capivasertib
November 23, 2023 13:00 - 23 minutes - 18.8 MBFDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.
Fruquintinib And Osimertinib-Chemo in Combo?
November 16, 2023 18:30 - 16 minutes - 13.4 MBThis week's Pod dives into a new VEGF-R inhibitor, fruquintinib. We also ask if FLAURA2, osimertinib + chemotherapy in combination, will become a new standard of care in EGFR-mutated metastatic NSCLC.
Elderly AML & Burkitt Lymphoma Updates
November 09, 2023 15:12 - 24 minutes - 19.4 MBAggressive hematologic malignancy publications can be challenging to interpret and translate to clinical practice. We look at two recent studies to illustrate this point. Elderly AML: 10-day decitabine vs. 7 + 3 (https://doi.org/10.1016/S2352-3026(23)00273-9) Burkitt Lymphoma: R-CODXO-M/R-IVAC vs. DA-R-EPOCH (https://doi.org/10.1016/S2352-3026(23)00279-X)
Landmarks Of Stage III NSCLC
November 02, 2023 18:25 - 14 minutes - 11.7 MBOut Landmarks of OncoPharm series returns to chronicle how treatment of stage III NSCLC has changed over time with an overview of three studies. 1. Dillman (1990) NEJM (sequential chemo --> RT): https://doi.org/10.1056/nejm199010043231403 2. Albain (1995) JCO (concurrent cisplatin/etoposide + RT): https://pubmed.ncbi.nlm.nih.gov/?term=7636530 3. Albain (2009) Lancet (concurrent cis/etposide + RT --> surgery --> consolidation chemo): https://doi.org/10.1016/s0140-6736(09)60737-6
ESMO 2023
October 26, 2023 15:09 - 28 minutes - 21.9 MBLots of practice changing new information came out of last week's ESMO conference. This Pod is packed with updates on NSCLC, bladder cancer, gastric cancer, medullary thyroid cancer, KRAS G12C colorectal cancer.....and even bendamustine (non-ESMO update).
Enzalutamide monotherapy? Plus, nivolumab & pembrolizumab approval updates
October 19, 2023 15:23 - 17 minutes - 13.5 MBThis week we discuss the continued push to introduce 2nd generation androgen inhibitors earlier into treatment with the EMBARK trial. Nivolumab and pembrolizumab, pemrolizumab and nivolumab. Again and again. Their role (and approvals) for adjuvant melanoma make sense. But what to think about their use for NSCLC in the neoadjuvant setting? West commentary: https://dailynews.ascopubs.org/do/should-induction-chemoimmunotherapy-lead-us-broaden-our-definition-resectability-nsclc
BRAF V600E Updates
October 12, 2023 19:18 - 16 minutes - 13 MBEncorafenib + binimetinib gets FDA-approval for metastatic NSCLC, but how does it compare to dabrafenib/trametinib? Plus, a new pediatric approval for dabrafenib/trametinib means more dosage form options.
Press Release Updates
October 05, 2023 15:58 - 14 minutes - 11.7 MBTrying to make sense of the limited information put out via Press Release the last 2 weeks for mobocertinib, pembrolizumab + enfortumab vedotin, nivolumab, and more.
Imatinib [Re-release]
September 28, 2023 11:17 - 19 minutes - 17.6 MBFrom the Foundations of OncoPharm archives - the history and groundbreaking STI 571 (imatinib).
Carboplatin Paclitaxel in Ovarian Cancer
September 21, 2023 16:57 - 11 minutes - 9.12 MBIt's another Landmarks of OncoPharm episode looking at the carboplatin-paclitaxel regimen in ovarian cancer from 20 years ago. carboplatin/paclitaxel vs. cisplatin/paclitaxel: https://pubmed.ncbi.nlm.nih.gov/?term=37643542
HER3-DXd & Motixafortide
September 14, 2023 16:15 - 11 minutes - 9.04 MBAn experimental drug for EGFRm NSCLC, patritumab deruxtecan (HER3-DXd), raises some eyebrows and a new agent is FDA-approved for hematopoietic stem cell mobilization (motixafortide).
RECISTance Is Futile
September 07, 2023 17:21 - 13 minutes - 10.8 MBYou read it in every solid tumor paper - RECIST - criteria. This Pod discusses some of the details of the Response Evaluation in Solid Tumors (RECIST) criteria along with the pros and cons of its use - including a modification of the criteria for use with immunotherapy.
DPYD Variant Dosing & ICIs In Pancreatic Cancer
August 31, 2023 14:50 - 19 minutes - 15.5 MBEmpiric dose reductions for variant DPYD alleles isn't necessarily new, but the outcomes of patients treated with those dose reductions isn't well described. Dutch researchers provide some much needed evidence. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651 Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh maybe probably. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37625102
Nab-Paclitaxel
August 24, 2023 17:55 - 15 minutes - 12.2 MBA Foundations of OncoPharm episode on nab-paclitaxel, with a focus on the pharmaceutical differences from conventional paclitaxel.
Niraparib + Abiraterone, Elranatamab, & Melphalan Updates
August 17, 2023 15:23 - 14 minutes - 11.4 MBA combination product is now available of niraparib + abiraterone for use in mCRPC. Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.
Talquetamab & STOP-CA
August 10, 2023 20:18 - 15 minutes - 12 MBTalquetamab is approved for r/r multiple myeloma and the STOP-CA trials asks if atorvastatin can prevent anthracycline cardiotoxicity. STOP-CA: https://jamanetwork.com/journals/jama/fullarticle/2807988
Ruby Trial & Quizartinib Toxicity
August 03, 2023 20:04 - 14 minutes - 11.5 MBThe Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients. Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.
BCOP Study Tips
July 27, 2023 17:42 - 13 minutes - 10.8 MBBy listener request! What is BCOP, why pursue it, and some simple tips on studying for the exam.
Chemotherapy Sequencing In Colorectal Cancer
July 20, 2023 17:35 - 13 minutes - 10.8 MBA Landmark of OncoPharm from 2004: FOLFIRI --> FOLFOX or FOLFOX --> FOLFIRI. Some interesting dosing to discuss in this study. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37379692
Phase 1 Clinical Trials In Oncology with Dr. Donald Harvey
July 13, 2023 17:00 - 39 minutes - 29.5 MBWe welcome Dr. Donald Harvey to the podcast to discuss Phase 1 clinical trials in oncology. Topics include goals of Phase 1 trials, how these early studies are conducted, how doses are determined, and some limitations of current practices.
Investigational Drug Services In Oncology with Dr. Jackie Saunders
July 06, 2023 17:00 - 29 minutes - 21.9 MBWe welcome Jacqueline (Jackie) Saunders to the podcast to talk about investigational drug services (IDS) in oncology and how pharmacists manage the storage, preparation, & delivery of experimental drugs.
NADIM II & Favorable Risk RCC
June 29, 2023 15:42 - 15 minutes - 12.4 MBThis episode... More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II. Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.) NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530 FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030
Glofitamab & TALAPRO - 2
June 22, 2023 14:59 - 12 minutes - 10.3 MBThis week's Pod looks at the 2nd CD20-CD3 bispecific T-Cell engager approved this year (or at all), glofitamab, and the TALAPRO-2 study of combining talazoparib to enzalutaimide. TALAPRO-2: https://doi.org/10.1016/S0140-6736(23)01055-3
ASCO '23 Entrees
June 15, 2023 17:49 - 27 minutes - 21.9 MBWe highlight notable data from this month's ASCO annual meeting. 1. SONIA: sequence (1st or 2nd-line) CKD 4/6i in MBC 2. ADAURA OS results and low rate of osimertinib use in control arm 3. Keynote 671: perioperative pembrolizumab in NSCLC 4. PROSPECT: Can radiation therapy be omitted in locally advanced rectal cancer? 5. Nivo-AVD vs. Bv-AVD in stage III Hodgkin's (ages 12+) 6. ZUMA-7: 2nd line Axl-Cel OS benefit in aggressive NHL (early relapse/refractory disease) 7. CARTITUDE-4: Cilta-Cel e...
PROpel and Cilostazol to Prevent Paclitaxel Neuropathy
June 01, 2023 17:37 - 17 minutes - 13.7 MBOlaparib + Abiraterone is FDA approved for mutated-BRCA prostate cancers. Olaparib has a bit of convoluted story to unpack in this patient population. Have we finally found a way to minimize the peripheral neuropathy from paclitaxel.....with cilostazol? PROpel: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043 Cilostazol RCT: https://doi.org/10.1002/phar.2830 Cilostazol effect on Schwann cells: https://doi.org/10.1016/j.neuropharm.2021.108514
Epcoritamab
May 25, 2023 18:22 - 15 minutes - 12.5 MBWe discuss the newly approved CD20-CD3 T-cell engager for subcutaneous (SC) administration to treat DLBLC after 2 or more lines of therapy.
Trimodality Treatment For Bladder Cancer
May 18, 2023 18:32 - 16 minutes - 13.1 MBA recent paper serves as a good prompt to discuss trimodality treatment for muscle-invasive bladder cancer and the data supporting its use. Zlotta et al: https://doi.org/10.1016/S1470-2045(23)00170-5
GAIA-CLL13 & COSMIC-313
May 11, 2023 16:35 - 22 minutes - 18.5 MBToday's Pod discusses... 1) A large trial comparing 4 different CLL treatments GAIA-CLL13: https://www.nejm.org/doi/full/10.1056/NEJMoa2213093 2)Adding Cabozantinib + Nivo/Ipo vs. Nivo/Ipi in intermediate/poor risk mRCC COSMIC-313: https://www.nejm.org/doi/full/10.1056/NEJMoa2212851 3) A potential future biomarker for predicting response to PD-(L)1 targeted therapies Functional PD-1/PD-L1 Engagement: https://pubmed.ncbi.nlm.nih.gov/?term=36821809
SUNLIGHT
May 04, 2023 19:39 - 13 minutes - 10.8 MBTalking 3rd-line treatment of metastatic colon cancer. Tipiracil-trifluridine + bevacizuamb vs. tipiracil-trifluridine alone. And a bit on the theory of "bevacizumab beyond progression." SUNLIGHT: https://www.nejm.org/doi/full/10.1056/NEJMoa2214963
QuANTUM First (Quizartinib 1st Line in AML)
April 27, 2023 19:25 - 18 minutes - 15.4 MBQuizartinib vs. Placebo(?) + Chemo in newly diagnosed AML. We add a bit of context about quizartinib's history leading up to this study preview possible role in therapy if approved in the future. Link: https://doi.org/10.1016/S0140-6736(23)00464-6
ICI + Bacterial Supplementation
April 20, 2023 19:44 - 12 minutes - 10.1 MBWe take a peak at an intriguing study (n = 29) that gave some metastatic RCC patients receiving nivolumab + ipilimumab a supplement of a bacterium (n = 19) and a control group. We discuss what to look for in the future studies that are likely to follow with similar methods.